| Dr Joel Christian Milligan, MD | |
|
2337 Homer Clayton Dr, Guntersville, AL 35976-2205 | |
| (256) 582-5131 | |
| (256) 582-1100 |
| Full Name | Dr Joel Christian Milligan |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 25 Years |
| Location | 2337 Homer Clayton Dr, Guntersville, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093829640 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 23625 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of Marshall County/shepherd's Cove | Albertville, AL | Hospice |
| Marshall Medical Centers | Boaz, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lakeside Clinic Llc | 8628980034 | 10 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
The deficit panel will have three months to recommend $1.5 trillion in deficit reductions over the next 10 years, with Medicare and Medicaid part of the mix. Republicans reacted by saying the picks were political moves and offered little hope of overcoming the continuing partisan stalemate.
A landmark study proves that children are capable of recovery from autism, or of making substantial gains in cognitive and adaptive functioning, as well as language skills, according to results released last night by Dr. Doreen Granpeesheh, founder of the Center for Autism and Related Disorders, Inc. (CARD).
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.
In response to the H1N1 flu, most employees at U.S. businesses say their company took measures to protect them from illness, such as encouraging sick employees to stay home, according to a national poll of employees by researchers from the Harvard Opinion Research Program at Harvard School of Public Health.
› Verified 9 days ago
| Entity Name | Lakeside Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477657823 PECOS PAC ID: 8628980034 Enrollment ID: O20031104000389 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
The deficit panel will have three months to recommend $1.5 trillion in deficit reductions over the next 10 years, with Medicare and Medicaid part of the mix. Republicans reacted by saying the picks were political moves and offered little hope of overcoming the continuing partisan stalemate.
A landmark study proves that children are capable of recovery from autism, or of making substantial gains in cognitive and adaptive functioning, as well as language skills, according to results released last night by Dr. Doreen Granpeesheh, founder of the Center for Autism and Related Disorders, Inc. (CARD).
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.
In response to the H1N1 flu, most employees at U.S. businesses say their company took measures to protect them from illness, such as encouraging sick employees to stay home, according to a national poll of employees by researchers from the Harvard Opinion Research Program at Harvard School of Public Health.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel Christian Milligan, MD 2337 Homer Clayton Dr, Guntersville, AL 35976-2205 Ph: (256) 582-5131 | Dr Joel Christian Milligan, MD 2337 Homer Clayton Dr, Guntersville, AL 35976-2205 Ph: (256) 582-5131 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
The deficit panel will have three months to recommend $1.5 trillion in deficit reductions over the next 10 years, with Medicare and Medicaid part of the mix. Republicans reacted by saying the picks were political moves and offered little hope of overcoming the continuing partisan stalemate.
A landmark study proves that children are capable of recovery from autism, or of making substantial gains in cognitive and adaptive functioning, as well as language skills, according to results released last night by Dr. Doreen Granpeesheh, founder of the Center for Autism and Related Disorders, Inc. (CARD).
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.
In response to the H1N1 flu, most employees at U.S. businesses say their company took measures to protect them from illness, such as encouraging sick employees to stay home, according to a national poll of employees by researchers from the Harvard Opinion Research Program at Harvard School of Public Health.
› Verified 9 days ago
Dr. Charles A Larson, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2337 Homer Clayton Drive, Guntersville, AL 35976 Phone: 256-582-5131 Fax: 256-582-1100 | |
Mrs. Lezlie Tamia Reed-johnson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2337 Homer Clayton Drive, Guntersville, AL 35976 Phone: 256-582-5131 Fax: 256-582-1100 | |
Dalton Evan Diamond, MD, MPH Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 67 Pine Needle Trce, Guntersville, AL 35976 Phone: 256-571-8923 | |
Mr. Jeffrey M Saylor, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2337 Homer Clayton Drive, Guntersville, AL 35976 Phone: 256-582-5131 Fax: 256-582-1100 | |
Dr. Stephen Brown Henderson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2308 Homer Clayton Dr, Guntersville, AL 35976 Phone: 256-582-2581 Fax: 256-582-7799 | |
Dr. Thomas Lloyd Darnell, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2308 Homer Clayton Dr, Guntersville, AL 35976 Phone: 256-582-2581 Fax: 258-582-7799 |